Stock Events

Stock Events

UroGen Pharma 

$44.09
27
-$0.79-1.76% 20:00 Today
+$0.84+1.91%22:13After hours

Statistics

Day High
44.76
Day Low
43.57
52W High
50.81
52W Low
15.86
Volume
8,564
Avg. Volume
-
Mkt Cap
2.16B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.05
-0.67
-0.28
0.1
Expected EPS
0.1025
Actual EPS
N/A

Financials

-139.81%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
109.79MRevenue
-153.49MNet Income

Analyst Ratings

55.20Average Price Target
The highest estimate is 75.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow URGN. It's not an investment recommendation.
Tesla
5
TSLA
NVIDIA
5
NVDA
Meta Platforms
5
META
Microsoft
4
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Nektar Therapeutics
NKTR
Mkt Cap2.48B
Nektar Therapeutics develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which could compete in the oncology and urology sectors similar to UroGen Pharma's focus.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.33B
Madrigal Pharmaceuticals focuses on the development of novel therapeutic candidates for significant unmet needs in oncology and diseases affecting the liver, directly competing with some of UroGen's therapeutic areas.
Exelixis
EXEL
Mkt Cap13.49B
Exelixis, Inc. is involved in the discovery, development, and commercialization of new medicines for the treatment of cancer, including urologic cancers, making it a direct competitor.
Incyte
INCY
Mkt Cap25.21B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology, competing in the same therapeutic areas as UroGen Pharma.
Karyopharm Therapeutics
KPTI
Mkt Cap42.41M
Karyopharm Therapeutics Inc. is focused on the discovery and development of drugs for the treatment of cancer and other major diseases, including areas that overlap with UroGen Pharma's focus.
Arvinas
ARVN
Mkt Cap600.25M
Arvinas, Inc. is pioneering the development of protein degradation therapeutics for the treatment of cancers, including those in UroGen Pharma's interest areas, making it a competitor.

About

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Show more...
CEO
Elizabeth Barrett
Employees
291
Country
Israel
ISIN
IL0011407140
WKN
000A2DTCV

Listings

STU
DE
UR8.STU
MU
DE
UR8.MU
F
DE
UR8.F
XNAS
US
URGN

0 Comments

Share your thoughts

FAQ

What is UroGen Pharma stock price today?▼
The current price of URGN is $44.09 USD — it has decreased by -1.76% in the past 24 hours. Watch UroGen Pharma stock price performance more closely on the chart.
What is UroGen Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange UroGen Pharma stocks are traded under the ticker URGN.
Is UroGen Pharma stock price growing?▼
URGN stock has risen by +1.08% compared to the previous week, the month change is a +10.45% rise, over the last year UroGen Pharma has showed a +134.52% increase.
What is UroGen Pharma market cap?▼
Today UroGen Pharma has the market capitalization of 2.16B
When is the next UroGen Pharma earnings date?▼
UroGen Pharma is going to release the next earnings report on November 05, 2026.
What were UroGen Pharma earnings last quarter?▼
URGN earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.27 USD resulting in a -5.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is UroGen Pharma revenue for the last year?▼
UroGen Pharma revenue for the last year amounts to 109.79M USD.
What is UroGen Pharma net income for the last year?▼
URGN net income for the last year is -153.49M USD.
How many employees does UroGen Pharma have?▼
As of September 04, 2026, the company has 291 employees.
In which sector is UroGen Pharma located?▼
UroGen Pharma operates in the Health & Wellness sector.
When did UroGen Pharma complete a stock split?▼
UroGen Pharma has not had any recent stock splits.
Where is UroGen Pharma headquartered?▼
UroGen Pharma is headquartered in RA'ANANA, Israel.